leadf
logo-loader
viewLiving Cell Technologies Ltd

Living Cell Technologies shares rise on positive initial Parkinson’s disease study results

The company’s shares are trading about 10% higher intra-day, at 5.6 cents.

Parkinson's disease
Parkinson's disease is a progressive nervous system disorder that affects movement.

Living Cell Technologies Ltd (ASX:LCT) has revealed statistically significant improvements in patients who received NTCELL capsule implantation on the brain, in the phase IIb study of NTCELL for Parkinson’s disease.

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of pathogen-free pigs.

Following implantation into a damaged site within the brain, NTCELL functions as a neurochemical factory secreting multiple nerve growth factors that promote new central nervous system growth and repair disease-induced nerve degeneration.

The study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.

Efficacy was measured using the Unified Parkinson’s Disease Rating Scale (UPDRS).

Initial data from the 18-month follow up of 18 patients show a statistically significant improvement (p = <0.05) in the UPDRS in the patients who received 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery.

No benefit was observed when 120 NTCELL capsules were implanted, there being evidence of inflammation which may have compromised efficacy in this group.

Auckland City Hospital principal investigator Dr Barry Snow said: “The statistical improvement seen at 12 months has been sustained; variation between recipients is expected with the small number of subjects.

“The next step is further in-depth analysis to understand the data on all efficacy measurements both on and off normal symptomatic treatment.”

Quick facts: Living Cell Technologies Ltd

Price: 0.016 AUD

ASX:LCT
Market: ASX
Market Cap: $9.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ora Banda Mining anticipating its first gold bar by the end of January

Ora Banda Mining Ltd's (ASX:OBM) David Quinlivan talks Proactive's Andrew Scott through its December quarterly update. He says they've now begun wet commissioning of the plant and will be progressively commissioning over the coming weeks with a view of getting the first gold bar out by the end...

12 hours, 49 minutes ago

2 min read